Address
665 Stockton Drive
Bothell, PA 19341
United States of America (the)
Phone
610 321 3700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
131
First IPO Date
October 02, 2020
| Name | Title | Pay | Year Born |
| Clay Siegall | Chairman, President & Chief Executive Officer | 1.41M | 1961 |
| Kinney Horn | Chief Business Officer | 598,862 | 1975 |
| Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary | 715,350 | 1973 |
| Robert J. Lechleider | Chief Medical Officer | 850,093 | 1961 |
| Jack Higgins | Chief Scientific Officer | 956,342 | 1980 |
| Max Rosett | Chief Financial Officer | 1.16M | 1990 |
| Roee Shahar | Executive Vice President of Commercial | 0 | N/A |
| Philip Tsai | Chief Technical Officer | 0 | 1968 |
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.